US FDA extends PDUFA goal date of Bristol Myers' sBLA for Reblozyl to treat anaemia in adults with NTD beta thalassemia

Bristol Myers Squibb, a global biopharmaceutical company, announced that the US Food and Drug Administration (FDA) has extended the review of the supplemental biologics license application (sBLA) for Reblozyl (luspatercept-aamt) [...]